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Despite its significant genetic component, the study of hypertension by genome-wide association presents more challenges than
other common complex diseases. Its high prevalence, heterogeneity, and somewhat unclear definition are the challenges that need
to be overcome on one hand. On the other hand, there are issues of small effect sizes and pleiotropism that are not specific to
hypertension alone but nonetheless magnify the problems of genetic dissection when coupled with phenotypic misclassification.
We discuss issues of study design and summarise published genome-wide association studies (GWASs) of hypertension and blood
pressure. With careful study design and analysis success is possible, as demonstrated by the recent large-scale studies. Following
these, there is still further scope to advance the field through high fidelity phenotyping and deep sequencing.
1. Introduction
Hypertension is the major factor responsible for the most
deaths worldwide (around 7 million or 12.8% per year)
and this is 46% more than tobacco usage, the next major
risk factor [1]. From an epidemiological and clinical per-
spective, blood pressure at the higher end of the normal
population distribution is associated with an increased risk
of cardiovascular mortality and morbidity. But clinical risk
assessment is based on a predefined threshold at which the
quantitative blood pressure phenotype in converted into
a binary trait (hypertension) and management strategies
are directed towards blood pressure reduction below this
threshold at which the risk of excess cardiovascular events
is abolished. Hence large-scale efforts to dissect the genetic
underpinnings of hypertension are justified. While the
causation of hypertension is multifactorial with both genetic
and environmental components, the purpose of this paper
is to discuss the genetic determinants of high blood pressure
and GWAS study design.
For any genetic study, the key initial step is phenotypic
specification. Here whether studying blood pressure as a
quantitative trait or the qualitative hypertension phenotype
depends on whether one follows the Pickering argument
that blood pressure is inherited as a “graded character,”
and hence a complex non-Mendelian trait, or the Platt
suggestion that hypertension is a qualitative abnormality
and a simple Mendelian disease [2]. The observed normal
unimodal distribution of blood pressure and its complex
multifactorial aetiology support studies of blood pressure as
a quantitative phenotype. According to the latter argument, if
hypertension is a dichotomous risk trait, one would expect a
bimodal distribution and this is not observed. However both
approaches are useful and complementary in the genetic
dissection of this trait which has so far been extremely
resistant to the GWAS approach.
2. Evidence for a Genetic Component in
Hypertension
There are multiple strands of evidence showing that genetic
factors contribute to blood pressure and hypertension.
Firstly, the normal distribution of blood pressure in the
general population indicates the presence of multiple envi-
ronmental and genetic factors and thus a polygenic aetiology.
Secondly, rare monogenic forms of hypertension associated
with major defects in renal salt handling prove that gene
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mutations can cause hypertension leading to a hypothesis
that minor variations in these genes may contribute to the
common essential hypertension. Finally from a population
perspective, there is considerable evidence from twins and
family aggregation studies indicating the presence of a
heritable component.
It is estimated that around 30% of variation in blood
pressure is due to genetic factors [3]. Hypertension is about
twice as common in individuals who have one or two
hypertensive parents, and blood pressure is more closely
correlated in monozygotic than dizygotic twins [4, 5]. In
the Montreal Adoption Study investigators compared blood
pressure correlation between biological sibling pairs and
adoptive sibling pairs (as well as parent-child correlations).
SBP correlation coefficients were 0.38 and 0.16 for biological
and adopted siblings, respectively, and DBP coefficients 0.53
compared with 0.29 respectively [6].
Two measures that are commonly used to assess the
genetic component of a trait are heritability (h2) which is the
fraction of variation in disease susceptibility due to genetic
factors, and sibling recurrent risk (λs) which is the degree of
elevated risk of disease for a sibling of an affected individual
compared with a member of the general population. The
heritability of clinic systolic blood pressure is around 15–
40% and 15–30% for clinic diastolic blood pressure [7, 8];
whereas for ambulatory night-time systolic and diastolic BP
the heritabilities are 69% and 51% [7]. It is pertinent to point
out that though the heritability estimates are considerable,
this does not equate to magnitude of genetic effect. This
is because the denominator in the estimate of heritability
comprises measurement error and variances attributable
to genes, shared environment, unshared environment and
unmeasured determinants. This is illustrated by the example
above where minimizing measurement errors by using
ambulatory night-time values inflates the heritability esti-
mates. Heritability is also a property of the population
studied and low heritability estimates would suggest that
genetic mapping would be difficult for that phenotype. The
sibling recurrent risk of hypertension is around 1.2–1.5 [9],
indicating a phenotype with modest genetic effect.
3. Strategies for Gene Mapping of
Complex Diseases
The field of common complex disease genetics has in
recent years moved from linkage to association study design
because association analysis has far greater power to detect
variants of modest effect and of lower frequency. The initial
successes of hypertension gene mapping have come from
studies of monogenic syndromes. The monogenic diseases
are examples of diseases which are under very strong
negative selection primarily because they affect fitness and
are less likely to be transmitted to the next generation.
The monogenic Mendelian forms of hypertension are thus
rare, and responsible gene mutations are highly penetrant,
and under very strong selection which keeps them at low
frequencies with high levels of allelic heterogeneity. Thus
these are highly amenable to linkage analysis. In contrast,
susceptibility variants involved in essential hypertension are
likely to have low or medium penetrance and are probably
not subject to such strong selection resulting in lower
allelic heterogeneity and greater prevalence of the trait. Thus
linkage analysis as expected has not really provided robust
validated loci for hypertension. To detect loci conferring
a genotypic relative risk of 1.5 (minor allele frequency
(MAF) = 0.1) by linkage analysis requires an estimated
67,816 affected sibling pairs (ASPs) whereas detection is
possible through association with just 2218 singletons [10].
Moreover it is easier to recruit participants from the general
population (than families as required for linkage), and there
are fewer sampling restrictions in some disease categories
such as late onset.
Association studies are typically performed in unrelated
population samples (although it is possible to conduct
them on related individuals). For qualitative traits they
measure statistical association between a disease (phenotype)
and genetic marker (genotype) directly by comparing allele
frequencies of cases and controls. The aim is to establish
whether a particular allele occurs in cases, compared with
controls, more frequently than expected by chance. Quan-
titative traits, for example, blood pressure, cholesterol, and
glucose, are assessed for association using linear regression.
GWAS is typically an indirect or map-based approach. This
measures the association between a phenotype and a marker
allele (or “tag” SNP), which is correlated with the true
causal allele due to linkage disequilibrium (LD). Linkage
disequilibrium is defined as “the statistical association,
within gametes in a population, of the alleles at two loci”
[11] (on the same chromosome). It is assumed that typically
a causal variant will not have been typed in GWAS which
take advantage of LD to genotype a set of tag SNPs as proxies
for the entire set of SNPs. The amount of LD between two
loci is summarised by the metric r2 (squared correlation
coefficient for each SNP) which varies between 0 and 1. The
maximum r2 can be used to translate coverage (measure of
how well the SNPs that are part of a genotyping set capture
all known variants) to the sample size that is required for
an indirect association study. To cover unobserved loci well
an r2 value of ≥ 0.8 with typed loci is considered sufficient
[12]. In general SNPs in LD are more likely to be inherited
together because they are physically close to each other
on the chromosome. But this is not necessarily the case;
studies have shown that levels of local LD vary, with some
adjacent SNPs being independent despite their proximity and
others of ≥100 kb apart being in a high or a significant LD
[13]. Patterns of LD are affected by many factors such as
population growth, population structure, admixture, natural
selection, genetic drift, rate of recombination and mutation,
and gene conversion [14].
Traditionally association studies tested hypotheses based
on candidate genes, for which there was prior evidence
(of known physiological pathways that affect the phenotype
in question) that a genetic variant influenced disease risk.
Unsurprisingly many of the candidate genes for hypertension
are involved in sodium balance. No candidate gene study has
yet demonstrated a reproducible association with hyperten-
sion [15]. There are several potential reasons for this, which
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highlight the drawbacks of candidate gene studies:
(i) the wrong genes may have been selected;
(ii) the causative genes may be upstream or downstream
from the genes studied;
(iii) discovery of genetic variants in novel pathways is not
possible as candidate gene studies rely on a priori
information regarding disease mechanisms.
In addition to the above there are the possibilities of pop-
ulation stratification, phenotypic and locus heterogeneity,
and insufficient sample size: problems common to candidate
gene studies and GWAS. Finally the SNPs studied might not
provide complete coverage of the variants within the genes.
4. The GWAS Strategy
The chance of detecting genetic variants that influence com-
mon disease depends on the underlying genetic architecture.
That is to say, the number of susceptibility alleles, whether
they are common or rare, their frequency, and whether
their action is neutral or deleterious. Allelic spectra vary
greatly between disease genes. Common alleles and those
of high frequency are of course easier to detect, as are
deleterious alleles. The entire GWAS strategy is based on
the Common Disease Common Variant (CDCV) hypothesis,
that the causative genes for common diseases have relatively
simple allelic spectra, that is, one or a few predisposing alleles
of relatively high frequency. For GWAS it has been suggested
that, as a rough guide, SNPs should meet a threshold of
MAF ≥ 1% [16] or MAF ≥ 5% [11] to be considered
common. As yet there is insufficient empirical evidence
to determine the validity of the CDCV hypothesis, and
arguments for and against have been put forward. These are
crucial to research using SNP mapping to predict common
disease risk, which assumes that the theory is by and large
accurate (linkage studies of families or ASPs, by contrast, are
robust to allelic heterogeneity).
A key part of the argument against the CDCV hypothesis
rests on the fact that the risk of common disease depends on
the interaction of many genes and environmental factors. In
particular late-onset disorders of high prevalence in modern
western society have been heavily influenced by changes in
lifestyle factors such as diet and physical activity, and not by
common disease-predisposing alleles. The risk conferred by
any one factor, whether genetic or environmental, is weak
and most cases are not predominantly determined by genetic
variance. On the other hand, the relative risks observed in
familymembers (amore rapid than linear decline in risk with
increasing distance of relationship) support the conclusion
that the majority of risk is due to a modest number of
loci with common disease-predisposing alleles. The existing
evidence suggests that alleles of both high and low frequency
play a part in common disease [17–22].
Wang et al. have argued against making a distinction
between rare and common disease-predisposing alleles [12].
Instead they propose that the allelic spectrum of disease
associated variants be considered in the context of all
variants in the human genome. In this framework the
neutral model is that the allelic spectrum of disease variants
and that of all variants are the same. Most susceptibility
variants would be rare (MAF < 1%); however SNPs with
MAF > 1% would still account for more than 90% of
genetic differences between individuals and therefore make
a significant contribution to phenotypic variation [23]. This
lies somewhere between the two opposing views regarding
the CDCV hypothesis. Common diseases vary in their allelic
spectra depending on the evolutionary forces exerted upon
them; nevertheless it is estimated that each will likely have
hundreds of common and rare variants contributing to their
familial clustering [12].
The International HapMap Project is a global consortium
mapping all common SNPs in different populations across
the world. The availability of SNP maps from HapMap led to
a revolution in the dissection of common diseases and traits
based on the common disease common variant hypothesis
using the GWAS approach. This is a hypothesis-generating
approach where no assumptions are made regarding the
location or function of the causal variant. The dense
genotyping chips that are now available contain hundreds
of thousands of tag SNPs and offer increasingly better
coverage of the human genome (whether within or outside
genes). Adequate coverage requires ≥300 000 SNPs with
more needed for African samples due to greater genetic
diversity in those populations [11] and thus less LD [24, 25].
Though there is some concern that a set of tag SNPs that
were selected in one population may not perform well in
another [11, 14], the availability of dense SNP arrays will
overcome this. There is also evidence of good tag SNP
transference across populations [26, 27]. This is especially
true for different populations within the same continent;
the greatest disparities are between African and non-African
samples.
While GWASs scan the genome for association signals
without selecting for gene regions, Jorgenson and Witte
have argued for a gene-centric approach to GWAS [28].
The reasons they outline are the following: genic variants
are more likely to be functionally important than nongenic;
variants in many genes are in lower LD than those outside
genes so may be difficult to capture through indirect
association. By focusing solely on genes and not the whole
genome there is potential to increase coverage of genes and
decrease the genotyping burden. The genic approach has
greater power to detect variants within genes but suffers from
a loss of power for nongenic variants. Despite this Jorgenson
and Witte demonstrated empirically using HapMap data
that it is more efficient in detecting causal variants than the
indirect whole-genome approach when related to genotyping
burden. Their suggestion of the best overall GWAS approach
is to combine indirect genotyping data with gene-based
SNPs in high priority regions, or alternatively to use a more
stringent LD threshold in genic regions to “over-capture”
genic SNPs.
A limitation of GWAS is that they are very expensive,
especially with the large sample sizes that are required
for small effects. However, technological advancements are
rapidly reducing the cost of genotyping. In a bid to further
reduce costs, some researchers have adopted a two-stage
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GWAS study approach. In stage 1 a proportion of the
samples are genotyped on all markers, and then in stage 2 a
proportion of these markers are genotyped in the remaining
samples [29]. Another approach to make studies more
economical is the use of common controls for several groups
of different disease cases. This was recently demonstrated
by the Wellcome Trust Case Control Consortium (WTCCC)
[30]. In 2008 Donnelly summarised all GWAS recorded
at that time in the National Human Genome Research
Institute catalogue [31], which amounted to more than 300
replicated associations for more than 70 common diseases
and quantitative traits [32]. As of September 2009, there
were more than 500 published GWAS at P ≤ 5 × 10−8 (see
Figure 1).
5. Study Design Issues in GWAS
5.1. Significance Thresholds. By convention statistical signif-
icance using frequentist methods is determined using the
P-value threshold of .05, with values below this considered
significant (i.e., there is evidence to reject the null hypothesis
of no effect). This is not appropriate for GWAS because
the large number of tests performed increases the chance
of type I error. An alternative threshold, proposed by Risch
and Merikangas and now widely adopted, is P < 5 ×
10−8, which corresponds to an equivalent false positive rate
of 5% for 1 000 000 independent tests of association [10].
This is calculated using the simple Bonferroni correction
for multiple testing, which calculates a new significance
threshold by dividing .05 by the number of tests performed.
In practice this is conservative as it does not take levels of LD
into account; the use of tagging SNPs means the genome can
be covered sufficiently with around half this number of SNPs
(i.e.,∼500 000). This threshold is preferable to the traditional
.05 but it has been argued that P value alone is not adequate
for assessing significance. In addition to the possibility of
false positives within a study, the issue of multiple testing
can be viewed in the context of replication across studies.
If several groups publish the same nominally significant
association and these are combined, then the problem arises
[11].
5.2. Statistical Power. Statistical power to detect a pheno-
type-genotype association is dependent upon the magnitude
of effect, the frequency of causal allele(s), and the sample
size. Moreover, for indirect association it is not only the
disease predisposing allele frequency that matters, but also
the marker allele (or tag SNP) frequency, and the power to
detect an association is the greatest when these frequencies
match [33]. The extent of LD also influences the likelihood
of observing an association. However if the effect size is
large this is less important with power being high even at
low to moderate LD. Effect size for case control studies is
measured as an odds ratio (OR), which estimates the odds of
an individual in a given exposure group (i.e., with a certain
genetic variant) being a case versus being a control. If the
OR is significantly greater than 1 then the variant confers
susceptibility to the disease, if it is significantly less than 1
then its effect is protective. Unfortunately large effects are
usually rare.
For common complex diseases most published genetic
effects have to date been modest (OR ∼ 1.1–1.5) [17, 34],
so a reasonable level of LD is necessary as well as the
disease allele being common and close to the marker allele
frequency. These conditions translate to a feasible sample
size of several thousands of cases and controls. An exception,
which no doubt increased expectations of similar findings,
is the association between APOE4 and late-onset Alzheimer
disease [35] for which the allelic OR is 3.3 [33]. As yet
only a small percentage of the human genome has been
subject to well-designed association study so it is unknown
whether the published effect sizes are representative of the
genome overall [12]. The effect sizes observed are expected
due to themultifactorial nature of the diseases concerned and
individually translate to only a small increase in population
absolute risk. Multiple common risk variants of small effect
have been combined theoretically, however, to construct
risk scores of greater practical significance. Studies of the
distribution of genetic effect sizes in other species such
as rodents, Drosophila melanogaster, crops, and livestock
suggest that there will be few genetic loci of large effect and
many loci of small effect [36–42]. This view is now widely
accepted in the field of common disease genetics [43].
5.3. Population Stratification. Population stratification acts
as a confounder and can result in artefactual evidence of
association [44–46]. It occurs when there are two or more
strata in a population, and both the risk of disease and
the frequency of marker alleles differ between strata. It
therefore may appear that the risk of disease is related to
the marker alleles when in fact it is not. A similar concept
is admixture, which refers to “the mixture of two or more
genetically distinct populations” [12]. The International
HapMap Project has demonstrated clear genetic differences
between geographically separated populations [47].
The effect of stratification on analysis increases with
increasing sample size because even modest levels of under-
lying population structure are amplified [48, 49]. This
has particular relevance to GWAS as they are employing
larger and larger samples. A final important point is that
confounding by population stratification tends to actually
decrease (counter intuitively) with increasing number of
ethnic groups [50]. This is because the direction of bias
may differ between groups so that the overall combined
effect is diluted. Whether population stratification is a real
concern or not, to avoid any possibility of bias it is now
commonplace in studies of unrelated cases and controls to
employ stratification detection and correction methods [46].
Aside from matching cases and controls for genetic
background and relevant environmental factors as well as
possible and straightforward adjustment for ethnic group,
a number of possible solutions to population stratification
have been proposed. One is genomic control (GC) which
employs detection and correction methods, for example, by
using a bank of randomly selected markers (preferably > 100
[11]) that are unrelated to the question of interest to assess
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Figure 1: Published genome-wide associations until Sept. 2009. 536 published GWAS at P ≤ 5 × 10−8 (reproduced with permission from
[31]).
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artefactual association [48, 51–53]. A scaling factor is then
applied to the association results to adjust for the level of
ethnic variation observed. A similar approach is structure
assessment (SA), which too uses unlinked genetic markers
for detection but then attempts to match homogeneous
subgroups of the sample for association analysis within these
subpopulations [54–57]. It is assumed that any significant
association observed within a subpopulation cannot be due
to population structure; there is an issue, however, about
how many subpopulations to apply since they are a theo-
retical concept [11]. Explicit detection/correction methods
by principal components analysis have also been employed
[58, 59]. Due to the large number of markers genotyped
in GWAS it is possible to detect low levels of stratification.
However, a caveat to all of these detection methods is that
with a large enough sample size even small biases will be
statistically significant and may lead to overcorrection.
5.4. Replication. Many published association findings have
failed to be replicated. This is partly due to the so-called
“winner’s curse,” which is a bias whereby genetic effect
size estimates are overestimated in initial discovery studies
of disease-predisposing variants. The degree of effect size
inflation can be reduced or eliminated by increasing sample
size, and several correction methods have been proposed
(e.g., [60, 61]). Technical bias can occur if cases and controls
are not genotyped and analysed together in the same way. It
is also thought that poor choice of controls and population
stratification affect data quality and therefore play a part
in replication failure. Meta-analyses that have examined
replication failure indicate that in the majority of instances
false positives are to blame [17, 62].
Replication of GWAS findings is as important as replica-
tion of candidate gene associations, if not more so. The large
number of SNPs studied in GWAS and resulting volume of
statistical tests performed increases the likelihood of observ-
ing type I errors, that is, false positives. In 2007 an NCI-
NHGRI (National Cancer Institute and the National Human
Genome Research Institute in the US) Working Group on
Replication in Association Studies published an excellent
summary of their recommendations on the reporting of
initial association studies and criteria for replication [63].
There are certain situations in which there are insufficient
participant numbers for replication, such as rare diseases or
environmental exposures. These concerns do not affect most
association studies of common diseases, though, so usually
replication is advised. A strategy that increases power over
that of individual studies andmay be more cost effective than
replication is meta-analysis of genome wide datasets [64, 65].
This collaborative way of working is increasingly common as
investigators attempt to detect loci with smaller effects.
6. GWAS of Hypertension/Blood Pressure
To date there have been few GWAS of hypertension and/or
blood pressure, with varying degrees of success in detecting
associations with genetic variants. The WTCCC, made up
of over 50 British research groups, conducted a GWAS
study of 2000 cases each for 7 complex diseases of major
public health importance; bipolar disorder, coronary artery
disease, Crohn’s disease, hypertension, rheumatoid arthritis,
type 1 diabetes, and type 2 diabetes. These were compared
with 3000 shared common controls that came from two
sources: 1500 from the 1958 British Birth Cohort and
1500 blood donors that were recruited for the project.
The 2000 hypertension cases were unrelated participants
from the British Genetics of Hypertension (BRIGHT) study
[9]. Over the entire genome there were 21 SNPs identified
with P values lower than the genome wide significance
threshold of 5× 10−7. Of these, 10 were known associations.
Unfortunately, of the 7 diseases of interest, hypertension
could be described as the loser in that it was not associated
with any SNPs at P < 5 × 10−7. Moreover there was no
evidence for any of the variants previously associated with
hypertension (at least partly due to some not being well
tagged by the Affymetrix chip, for example, promoter of the
WNK1 gene). There were, however, a similar number and
distribution of marginal results (with P-values between 10−4
and 10−7) to the other case groups.
It was speculated that the lack of a positive result for
hypertension in the WTCCC study may have been due
to poorly tagged variants or that hypertension may have
few common risk alleles with larger effect sizes. Further-
more, misclassification bias may have reduced the power of
detecting effects. The common controls were not specifically
phenotyped for blood pressure. Due to the high prevalence
of hypertension and its existence on the continuum of blood
pressure some of the controls may have been misclassified
cases. It was estimated that the misclassification of 5% of
controls (i.e., if 5% of controls were in fact undiagnosed
cases) would translate to a loss of power equivalent to a 10%
reduction in sample size [30]. This is because of the dilution
of any observable genetic difference, caused by the blurring
of the distinction between cases and controls. Considering
the expense of genome-wide association analysis and the
anticipated relatively small effect sizes any reduction in
power poses a serious problem. Moreover individuals with
blood pressure in themid-range of normotension (that is not
considered to pose a risk clinically) may still be at increased
risk in relation to individuals with low-blood pressure.
Two recent studies that have had considerably more
success are the Global Blood Pressure Genetics (Global
BPgen) Consortium study, conducted by Newton-Cheh et al.
(2009) [71], and the Cohorts for Heart and Aging Research
in Genome Epidemiology (CHARGE) Consortium study,
conducted by Levy et al. (2009) [72]. But in contrast to
the WTCCC, these were studies of blood pressure as a
quantitative trait and on hypertension. Both had very large
discovery samples, providing sufficient power to overcome
variations in genotyping platform, participant ascertain-
ment and method of blood pressure measurement between
component studies. Each dealt with the confounding effect
of antihypertensive medication by adding 15mmHg to
recorded SBP and 10 mmHg to DBP for those who were on
such treatment.
In the Global BPgen discovery GWAS (N = 34, 433)
two SNPs achieved P < 5 × 10−8 (considered genome wide
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Table 1: Summary of recent GWAS of hypertension and/or blood pressure.
Publication date Phenotype
Discovery sample Discovery and replication meta-analysis
N OR/beta Lowest P-value N OR/beta P-value
Levy et al. [66] Sept-07
DBP 1233 — 3.31 × 10−6 — — —
SBP 1260 — 1.69 × 10−6 — — —
∗Wang et al. [67] Jan-09 SBP 542 — 7.6 × 10−5 7125 1.9 1.6 × 10−7
Org et al. [68] Mar-09 hypertension 364/596 0.49 2.34 × 10−6 3808/4334 0.78 1.39 × 10−6
Cho et al. [69] May-09 SBP 8842 −1.309 9.1 × 10−7 16703 −1.064 1.3 × 10−7
Adeyemo et al. [70] Jul-09
DBP 8842 −0.882 1.2 × 10−6 16703 −0.63 3.0 × 10−6
SBP 1017 — 4.72 × 10−8 — — —
DBP 1017 — .448 1997 — .162
hypertension 509/508 0.58 5.10 × 10−7 875/1122 — .009
∗
Observed an SNP with a lower P-value but did not report on it as situated in gene desert.
—Value not reported (or in the case of meta-analysis replication not attempted).
significance for this analysis). Once these and borderline
significant findings were meta-analysed with validation data
there were eight loci associated with either DBP or SBP
genome-wide. Investigators also assessed whether these loci
were associated with hypertension. The initial GWAS was
not conducted for hypertension due to lack of power,
so instead the significant loci were examined in planned
secondary analysis (N range = 57, 410–99, 802). In the
secondary samples all eight alleles showed association with
hypertension in the same direction of effect as continuous
blood pressure. It should be noted that all of the reported
associations translate to a very small change in blood pres-
sure, approximately 1mmHg per allele SBP or 0.5mmHg
per allele DBP. However, the effects of multiple variants can
be combined to produce a meaningful change in population
cardiovascular risk.
Taking a genome wide significance threshold of P <
4 × 10−7, the CHARGE discovery GWAS (N = 29, 136)
identified 13 significant SNP associations for SBP, 20 for DBP,
and ten for hypertension. There is quite a bit of overlap
between phenotypes with many of the top hits attaining
significance in the same direction of effect for more than one
phenotype.
The top ten loci for SBP, DBP, and hypertension (30 in
total) in the CHARGE cohort were checked for significance
in the Global BPgen results. One SNP for SBP, four for DBP,
and one for hypertension were assessed for independent
replication in Global BPgen. Five SNPs out of this six attained
P < .008, the threshold for external replication in Global
BPgen.When the results for the same 30 SNPs in both studies
were analysed together by meta-analysis, there were four
associations of genome wide significance (P < 5 × 10−8) for
SBP, six for DBP, and one for hypertension. Again effect sizes
were very small, approximately 1mmHg change in SBP per
allele or 0.5mmHg change in DBP per allele.
The remaining published studies have demonstrated far
less success in identifying genetic variants that are associated
with either hypertension, SBP, or DBP. Many have not
observed any SNPs that reached genome-wide significance
[66, 67, 73–75]. One possible reason for this failure in some
studies is that hypertension and/or blood pressure were not
the primary trait of interest [73], or not of a priori interest
when the cohort was recruited [75] therefore phenotyping
may not have been necessarily thorough. Another possibility
is that there were not enough SNPs studied to provide
sufficient coverage of the whole genome; in some studies
fewer than 100 000 SNPs passed quality control measures
[66, 67, 74].
Table 1 summarises the most significant hits from GWAS
of hypertension and/or blood pressure published since
2007 (other than WTCCC, Global BPgen, and CHARGE),
along with meta-analysed discovery and replication results
if replication was attempted. One study conducted by Sabatti
et al. [75] is omitted from the table because the authors did
not publish any results for blood pressure, instead reporting
that analysis of blood pressure did not produce any genome-
wide significant results. However it was not the primary trait
of interest; the authors also studied triglycerides, HDL, LDL,
CRP, glucose, insulin, and BMI.
Levy et al. [66] and Wang et al. [67] failed to find any
associations of genome-wide significance but had limited
genomic coverage, studying just 70,897 and 79,447 SNPs,
respectively. Furthermore the discovery sample employed by
Wang et al. was small at 542 participants. Org et al. [68] and
Cho et al. [69] also did not find any associations of genome-
wide significance.
The vast majority of GWAS thus far have been conducted
on samples of Caucasian individuals of European ancestry.
One of the few studies to examine African Americans was
that of Adeyemo et al. [70]. Their initial findings were
promising; however replication was either not attempted
(in the case of SBP) or the replication findings were in the
opposite direction of effect (DBP and hypertension).
7. Future Directions
Following an initial dearth of positive results from GWAS
of hypertension and blood pressure, the methodological
advancement and achievements of recent studies provide
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optimism and guidance for continued work in this area.
Where to now in the search for further novel gene poly-
morphisms? One approach that has been proposed to
increase the likelihood of detecting genetic effects is the
recruitment of hypercontrols and individuals with severe
hypertension [15]. This requires high fidelity phenotyping,
with the overall study design comparing cases and controls
at the extreme high and low ends, respectively, of the blood
pressure distribution. This would markedly reduce the risk
of misclassification bias and thus minimise any resultant loss
of power.
Much of the unexplained variation in blood pressure
may be due to rare variants that are undetectable through
traditional GWAS case-control study design. However, inten-
sively genotyped samples are becoming available from the
1000 Genomes Project, an open resource catalogue of human
genetic variation [76]. The project is run by an international
consortium and aims to describe over 90% of genetic
variation down to 1% MAF. To date the genomes of more
than 1000 individuals have been sequenced (with planned
expansion to 2000 individuals in 2010) and around 10
million novel variants identified. The resource will enable
the study of low frequency variants and aid fine mapping
of regions of interest. Furthermore, next-generation deep
sequencing technology is now available which will also
increase the chances of rare variant detection [77]. All of this
is carried out with the ambition to improve the diagnosis and
treatment of this widespread condition.
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